The Stockholm Stock Exchange began Wednesday's trading with an irregular trend.
After 25 minutes of trading, the OMXS30 index was up 0.13 percent to 2,816.62. During the day, the index has moved within a range of 0.13 percent at its lowest and 0.32 percent at its highest.
The broad OMXSPI was up 0.02 percent.
In the news flow, fertility company Vitrolife is taking a goodwill write-down of SEK 5.4 billion in connection with the acquisition of Igenomix. The company is also implementing a restructuring in which 6 percent of the workforce will be laid off. This will result in one-time costs of SEK 55 million, which will generate annual savings of SEK 65 million.
Cybersecurity company Yubico has had a difficult year, and CEO Mattias Danielsson is now stepping down. Chief Operating Officer Jerrod Chong will take over as acting CEO. Furthermore, Hansa Biopharma is falling after negative study results.
Companies
Change
Comment
AQ Group
2.7
SEB raises to buy (hold), target price SEK 206 (195)
Coffee Stain
2.6
SEB and SB1 Markets initiate coverage with a buy recommendation, Nordea initiates with hold
Embracer
2
Nordea resumes coverage with a buy recommendation and a target price of SEK 80
Bravida
1
Signs framework agreement in Denmark worth DKK 300 million
Yubico
-
CEO Mattias Danielson resigns, COO Jerrod Chong becomes acting CEO
SKF
-
JP Morgan puts the stock on negative catalyst watch
Vitrolife
-
Takes goodwill write-down of SEK 5.4 billion, cost-cutting program where 6 percent of staff will be laid off
Rejlers
-
Handelsbanken downgrades to hold (buy), target price SEK 215 (229)
Hansa Biopharma
-
Did not achieve primary efficacy endpoint in phase 3 study for anti-GBM
Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
